Limits...
Asthma pharmacogenetics and the development of genetic profiles for personalized medicine.

Ortega VE, Meyers DA, Bleecker ER - Pharmgenomics Pers Med (2015)

Bottom Line: Genetic profiles will consist of gene variants that predict individual disease susceptibility and risk for progression, predict which pharmacologic therapies will result in a maximal therapeutic benefit, and predict whether a therapy will result in an adverse response and should be avoided in a given individual.Pharmacogenetic studies of the glucocorticoid, leukotriene, and β2-adrenergic receptor pathways have focused on candidate genes within these pathways and, in addition to a small number of genome-wide association studies, have identified genetic loci associated with therapeutic responsiveness.The benefit of a personalized, tailored approach to health care delivery is needed in the development of expensive biologic drugs directed at a specific biologic pathway.

View Article: PubMed Central - PubMed

Affiliation: Center for Genomics and Personalized Medicine Research, Pulmonary Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

ABSTRACT
Human genetics research will be critical to the development of genetic profiles for personalized or precision medicine in asthma. Genetic profiles will consist of gene variants that predict individual disease susceptibility and risk for progression, predict which pharmacologic therapies will result in a maximal therapeutic benefit, and predict whether a therapy will result in an adverse response and should be avoided in a given individual. Pharmacogenetic studies of the glucocorticoid, leukotriene, and β2-adrenergic receptor pathways have focused on candidate genes within these pathways and, in addition to a small number of genome-wide association studies, have identified genetic loci associated with therapeutic responsiveness. This review summarizes these pharmacogenetic discoveries and the future of genetic profiles for personalized medicine in asthma. The benefit of a personalized, tailored approach to health care delivery is needed in the development of expensive biologic drugs directed at a specific biologic pathway. Prior pharmacogenetic discoveries, in combination with additional variants identified in future studies, will form the basis for future genetic profiles for personalized tailored approaches to maximize therapeutic benefit for an individual asthmatic while minimizing the risk for adverse events.

No MeSH data available.


Related in: MedlinePlus

Premise of pharmacogenetics research in complex diseases.Notes: Pharmacogenetics research studies a gene-by-environment interaction, by analyzing the effect of genotype and exposure to a medication in determining interindividual responses to pharmacologic therapies. Reprinted from Immunol Allergy Clin North Am. 2007;27(4). Ortega VE, Hawkins GA, Peters SP, Bleecker ER. Pharmacogenetics of the beta 2-adrenergic receptor gene. 665–684; vii. Copyright © 2007 with permission from Elsevier.83Abbreviation: SNP, single nucleotide polymorphism.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4325626&req=5

f1-pgpm-8-009: Premise of pharmacogenetics research in complex diseases.Notes: Pharmacogenetics research studies a gene-by-environment interaction, by analyzing the effect of genotype and exposure to a medication in determining interindividual responses to pharmacologic therapies. Reprinted from Immunol Allergy Clin North Am. 2007;27(4). Ortega VE, Hawkins GA, Peters SP, Bleecker ER. Pharmacogenetics of the beta 2-adrenergic receptor gene. 665–684; vii. Copyright © 2007 with permission from Elsevier.83Abbreviation: SNP, single nucleotide polymorphism.

Mentions: Pharmacogenetics is an important focus of asthma genetics research that evaluates a gene-by-environment interaction where environment is the exposure to a pharmacologic therapy and the outcome of interest is phenotype alteration in response to the therapy (which may include adverse effect phenotypes, Figure 1). The heritability of pharmacologic responses was initially observed in twin-based studies and clinical trials showing that intraindividual (within the same individual) responses to particular therapies vary much less than interindividual (between different individuals) responsiveness.7,8 Pharmacogenetic studies of the glucocorticoid, leukotriene, and β2-adrenergic receptor pathways have primarily focused on candidate genes within these pathways and have identified genetic loci associated with therapeutic responsiveness in asthma (Tables 1–3).


Asthma pharmacogenetics and the development of genetic profiles for personalized medicine.

Ortega VE, Meyers DA, Bleecker ER - Pharmgenomics Pers Med (2015)

Premise of pharmacogenetics research in complex diseases.Notes: Pharmacogenetics research studies a gene-by-environment interaction, by analyzing the effect of genotype and exposure to a medication in determining interindividual responses to pharmacologic therapies. Reprinted from Immunol Allergy Clin North Am. 2007;27(4). Ortega VE, Hawkins GA, Peters SP, Bleecker ER. Pharmacogenetics of the beta 2-adrenergic receptor gene. 665–684; vii. Copyright © 2007 with permission from Elsevier.83Abbreviation: SNP, single nucleotide polymorphism.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4325626&req=5

f1-pgpm-8-009: Premise of pharmacogenetics research in complex diseases.Notes: Pharmacogenetics research studies a gene-by-environment interaction, by analyzing the effect of genotype and exposure to a medication in determining interindividual responses to pharmacologic therapies. Reprinted from Immunol Allergy Clin North Am. 2007;27(4). Ortega VE, Hawkins GA, Peters SP, Bleecker ER. Pharmacogenetics of the beta 2-adrenergic receptor gene. 665–684; vii. Copyright © 2007 with permission from Elsevier.83Abbreviation: SNP, single nucleotide polymorphism.
Mentions: Pharmacogenetics is an important focus of asthma genetics research that evaluates a gene-by-environment interaction where environment is the exposure to a pharmacologic therapy and the outcome of interest is phenotype alteration in response to the therapy (which may include adverse effect phenotypes, Figure 1). The heritability of pharmacologic responses was initially observed in twin-based studies and clinical trials showing that intraindividual (within the same individual) responses to particular therapies vary much less than interindividual (between different individuals) responsiveness.7,8 Pharmacogenetic studies of the glucocorticoid, leukotriene, and β2-adrenergic receptor pathways have primarily focused on candidate genes within these pathways and have identified genetic loci associated with therapeutic responsiveness in asthma (Tables 1–3).

Bottom Line: Genetic profiles will consist of gene variants that predict individual disease susceptibility and risk for progression, predict which pharmacologic therapies will result in a maximal therapeutic benefit, and predict whether a therapy will result in an adverse response and should be avoided in a given individual.Pharmacogenetic studies of the glucocorticoid, leukotriene, and β2-adrenergic receptor pathways have focused on candidate genes within these pathways and, in addition to a small number of genome-wide association studies, have identified genetic loci associated with therapeutic responsiveness.The benefit of a personalized, tailored approach to health care delivery is needed in the development of expensive biologic drugs directed at a specific biologic pathway.

View Article: PubMed Central - PubMed

Affiliation: Center for Genomics and Personalized Medicine Research, Pulmonary Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

ABSTRACT
Human genetics research will be critical to the development of genetic profiles for personalized or precision medicine in asthma. Genetic profiles will consist of gene variants that predict individual disease susceptibility and risk for progression, predict which pharmacologic therapies will result in a maximal therapeutic benefit, and predict whether a therapy will result in an adverse response and should be avoided in a given individual. Pharmacogenetic studies of the glucocorticoid, leukotriene, and β2-adrenergic receptor pathways have focused on candidate genes within these pathways and, in addition to a small number of genome-wide association studies, have identified genetic loci associated with therapeutic responsiveness. This review summarizes these pharmacogenetic discoveries and the future of genetic profiles for personalized medicine in asthma. The benefit of a personalized, tailored approach to health care delivery is needed in the development of expensive biologic drugs directed at a specific biologic pathway. Prior pharmacogenetic discoveries, in combination with additional variants identified in future studies, will form the basis for future genetic profiles for personalized tailored approaches to maximize therapeutic benefit for an individual asthmatic while minimizing the risk for adverse events.

No MeSH data available.


Related in: MedlinePlus